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MaThis review provides an integrative and forward-looking perspective on the gamut of coronary physiology for the
diagnosis and management of atherosclerosis. Because clinical events serve as the ultimate gold standard, the future of
all diagnostic tests, including invasive fractional ﬂow reserve and noninvasive coronary ﬂow reserve, depends on their
ability to improve patient outcomes. Given the prominent role of acute coronary syndromes and invasive procedures in
cardiology, we practically consider 2 broad categories of patients with coronary disease: acute and stable. For patients
with acute coronary disease, coronary physiology may potentially reﬁne treatment of the culprit lesion. For both patients
with stable and acute nonculprit disease, reducing hard endpoints with revascularization potentially occurs at the
severe end of the focal physiological spectrum, an area under-represented in existing trials. Nonepicardial disease
and diffuse atherosclerosis remain underexplored aspects of coronary physiology for testing of novel treatments.
(J Am Coll Cardiol 2016;67:2772–88) © 2016 by the American College of Cardiology Foundation.T his review provides an integrative andforward-looking perspective on the gamutof coronary physiology for the diagnosis
and management of atherosclerosis. It ranges from
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
CABG = coronary artery bypass
graft
CAD = coronary artery disease
CFR = coronary ﬂow reserve
FFR = fractional ﬂow reserve
HMR = hyperemic
microvascular resistance
IMR = index of microcirculatory
resistance
MI = myocardial infarction
PCI = percutaneous coronary
intervention
PET = positron emission
tomography
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2773we extrapolate from pre-ACS coronary physiology,
leading to testable hypotheses for personalized inter-
ventions. The Central Illustration provides a visual
summary of the paper.
THE GOLD STANDARD
Clinical outcomes serve as the ultimate gold standard
for diagnostic tests. Unlike a therapy that directly
affects patients, a useful diagnostic test must inﬂu-
ence management decisions that in turn alter out-
comes. As evidence of this trend, several recent
reports highlight the surprisingly small effect of most
noninvasive cardiac stress testing on clinical care
(7–9). The ongoing ISCHEMIA (International Study of
Comparative Health Effectiveness with Medical and
Invasive Approaches) trial asks if abnormal stress test
results can change hard endpoints of death and
myocardial infarction (MI) using revascularization
(10). Thus, the future of all diagnostic tests depends
on their ability to improve patient outcomes.
Within the broad community of diagnostic tests,
measurements like fractional ﬂow reserve (FFR) and
coronary ﬂow reserve (CFR) belong to the category of
clinical coronary physiology. Invasively, we can
directly measure intracoronary pressure and ﬂow
(and indirectly speak of resistance), whereas non-
invasively, we can image myocardial perfusion (in
either relative or absolute units). Although a deep
foundation of basic physics, molecular and genetic
mechanisms, and fundamental animal and human
physiology underlie these tools, our goal as physi-
cians remains pragmatic: how can we help the patient
before us?
Consequently, we reframe this review as a discus-
sion of an important tool to improve the end goal of
patient well-being. To remain practical, we consider
2 broad categories of patients with CAD: acute and
stable. For decision-making and ethical, informed
discussion with patients, we distinguish among 3
easily understood outcomes: death, MI, and angina.
Although themost common therapeutic decisionmade
using coronary physiology remains revascularization,
we also consider customized medical therapy distinct
from treating general risk factors, as detailed later.
PATIENTS WITH ACUTE CORONARY DISEASE
Existing studies of patients with acute coronary
disease provide 3 profound, but often overlooked
insights for assessing physiologically-guided inter-
ventions. First, simultaneous “perfect storms”
causing an MI in 2 or more distinct coronary arteries
in the same patient are rare. Second, the majority of
ACS arises from a very severe lesion that evolvedrapidly via sequential, asymptomatic plaque
ruptures that healed with progressive steno-
sis (3,4,11). Third, the long-term risk after
revascularized ACS typically returns to the
background level of patients with known, but
stable CAD. These 3 insights together suggest
that nonculprit stenosis in patients with acute
coronary disease likely reﬂects the same
background of disease known to exist in pa-
tients with stable coronary disease, in
contrast to the culprit lesion, whose revas-
cularization without physiological assess-
ment has already been shown to reduce death
and MI (12). As such, the concepts derived for
stable CAD likely apply to the nonculprit le-
sions noted at the time of acute presentation,
thereby linking the 2 scenarios. Therefore,
this connection and commonality necessi-
tates our initially reviewing acute manifestations.
Acute presentations account for approximately
70% to 80% of the contemporary total number
of patients undergoing coronary revascularization
(13,14), an inversion of the balance from 25 years ago
(14). Due to improved clinical outcomes demon-
strated in randomized trials, most patients with acute
coronary disease proceed directly to invasive angiog-
raphy and revascularization of culprit lesions without
physiological assessment. However, as detailed next,
2 key questions have emerged recently and need
future answers. First, can physiology reﬁne treatment
in the culprit vessel in some patients? Second, if
intervention on nonculprit stenosis fails to reduce
death and MI, howmuch do patients value a reduction
in future revascularization procedures? Deﬁnitive
answers will require trials in large populations with
rational selection criteria and hard endpoints.
ROUTINE INVASIVE ANGIOGRAPHY WITHOUT
PHYSIOLOGICAL ASSESSMENT. The deﬁnition of
acute MI includes “imaging evidence of new loss of
viable myocardium” (15), thereby acknowledging
the need for noninvasive perfusion imaging to clarify
the diagnosis in some cases. However, relying on
noninvasive testing or symptoms to guide invasive
angiography in patients with acute coronary disease
with non-ST-segment elevation myocardial infarction
(NSTEMI), a “selective invasive” strategy, has proved
inferior to immediate angiography, a “routine inva-
sive” strategy (12). Speciﬁcally, routine compared
with selective angiography reduced cardiovascular
death (from 8.1% to 6.8%; hazard ratio [HR]: 0.83;
95% conﬁdence interval [CI]: 0.68 to 1.01; p ¼ 0.068)
and MI (from 12.9% to 10.0%; HR: 0.77; 95% CI: 0.65
to 0.90; p ¼ 0.001) over 5 years (12). The relative
reduction in events remained constant across the
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A visual summary and outline of this review begins by considering 2 general types of patients: acute (left) and stable (right). For patients with acute coronary disease,
coronary physiology can be directed at either the culprit or nonculprit stenosis. For patients with stable coronary disease, coronary physiology can identify patterns
of focal, diffuse, and microvascular disease. Each category lists key questions (thin box) with an image and summary of major messages. Images reprinted
with permission from Johnson et al. (85,98,99) and Gould et al. (100). CAD ¼ coronary artery disease; CFR ¼ coronary ﬂow reserve; FFR ¼ fractional ﬂow reserve;
NSTEMI ¼ non–ST-segment myocardial infarction; PCI ¼ percutaneous coronary intervention; PET ¼ positron emission tomography; RCT ¼ randomized controlled trial;
STEMI ¼ ST-segment elevation myocardial infarction.
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2774spectrum of absolute risk. Thus, the largest beneﬁts
from a routine invasive strategy accrued to the
highest-risk patients—a theme that will re-emerge
later for stable populations as well. For ST-segment
elevation myocardial infarction (STEMI) patients un-
dergo rapid cardiac catheterization and mechanical
reperfusion when geographically available, or intra-
venous lytic treatment and transfer for angiography
within 24 h if invasive management exists only
distantly (16,17).
WHAT IS THE ACUTE CULPRIT LESION: A ROLE FOR
CORONARY PHYSIOLOGY? In the majority of ACS, a
single culprit lesion can be identiﬁed using a com-
bination of angiographic appearance, regional left
ventricular dysfunction, and localizing electrocar-
diographic changes. Some patients have no obvious
culprit, whereas rare patients have 2 simultaneous
culprits.For patients with no obvious culprit, a wide dif-
ferential diagnosis exists, including both non-
coronary (e.g., pulmonary embolism or myocarditis)
and coronary (e.g., spasm or dissection) etiologies.
Depending on the clinical context, invasive physi-
ology provides objective quantiﬁcation of stenosis
severity as a potential cause of the acute presentation
because the majority of older individuals with risk
factors have some degree of atherosclerosis (18). For
example, a high FFR value may direct the clinician
to search for an alternative diagnosis, such as
pulmonary embolism (19). Alternatively, advanced
physiological assessment may uncover a host of
abnormalities (20), although establishing causal links
with the presentation and proven courses of treat-
ment remains difﬁcult.
CULPRIT LESION PHYSIOLOGY TO GUIDE TREATMENT.
For patients with 1 or more culprit lesions, invasive
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inversely, may augment revascularization. A recently
completed feasibility study, FAMOUS-NSTEMI
(Fractional Flow Reserve vs. Angiography in
Guiding Management to Optimize Outcomes in
Non-ST-Elevation Myocardial Infarction), examined
the hypothesis that using FFR to defer
revascularization for NSTEMI lesions of at least 30%
diameter stenosis with normal TIMI (Thrombolysis
In Myocardial Infarction) ﬂow may provide beneﬁt
(21). Although the study included both culprit and
nonculprit lesions, there were late spontaneous
major adverse cardiac events in 4 of 10 patients who
changed from percutaneous coronary intervention
(PCI) to medical therapy in culprit arteries by FFR
>0.8, which calls into question the long-term safety
of mixing both types of lesions.
After treatment of an acute culprit lesion, coronary
physiology measurements have been associated with
long-term prognosis (22,23). Because acute lesions
injure downstream myocardium, measures of micro-
vasculature resistance (related directly to coronary
pressure, but inversely to ﬂow) may provide insights
beyond FFR, which focuses on epicardial stenosis.
After STEMI, serial invasive measurements in the
culprit artery showed decreasing microvascular
resistance and increasing CFR over the subsequent
6 months (24), reﬂecting some myocardial recovery
after an acute event.
Depending on the speciﬁc intracoronary sensor,
either of 2 resistance indexes can be measured:
hyperemic microvascular resistance (HMR) using
Doppler ﬂow velocity (25) or the index of microcircu-
latory resistance (IMR) using bolus thermodilution
(26). Both HMR (27) and IMR (28) measured in the
culprit vessel after primary PCI for STEMI show a sig-
niﬁcant, inverse association with subsequent prog-
nosis. Thus, one may ask if this outcome spectrum can
be modiﬁed by treatment to reduce myocardial resis-
tance, or if high resistance is simply a risk marker
associated with confounders, such as infarct size and
ejection fraction. Ongoing intervention trials evalu-
ating the efﬁcacy of intracoronary glycoprotein IIb/IIIa
inhibitors (29), aspiration thrombectomy (29–31), nic-
orandil (32), and oral antiplatelet agents (33) are using
IMR as a primary or secondary endpoint in patients
with acute coronary disease. However, no randomized
trial has validated IMR or HMR as a therapeutic guide
for meaningful clinical endpoints of death or MI.
We conclude that although coronary physiology of
the acute culprit lesion may provide ancillary infor-
mation of potential interest, it should not be used
until supported by future, deﬁnitive, outcomes-based
randomized trials.CORONARY PHYSIOLOGY OF NONCULPRIT LESIONS.
Depending on the population and precise deﬁnition
of angiographic severity, a nonculprit, or “bystander”
or “incidental,” lesion is found in approximately
50% of patients presenting acutely (17). Currently,
no consensus exists regarding proper treatment.
European guidelines state that “the best strategy for
STEMI patients with multivessel disease, who un-
derwent primary PCI of the infarct-related artery in
the acute phase with remaining multivessel disease,
is still not well established” (16). American guidelines
note the “great variability in the evaluation and
management of nonculprit coronary artery disease
in stable patients without [heart failure] or shock,
both at the time of primary PCI and later during the
hospital course” (17).
Three recent randomized trials of managing
nonculprit stenosis in ACS have been completed,
with several others ongoing. Heterogeneity and
subjectivity of anatomic deﬁnitions for multivessel
disease led to trials that incorporated invasive
coronary physiology. As examples of anatomic
variation, the PRAMI (Preventive Angioplasty in
Acute Myocardial Infarction) trial used a 50%
diameter stenosis limit (34), whereas the CvLPRIT
(Complete Versus Lesion-Only Primary PCI) trial
allowed over 70% in a single view or over 50% in 2
views (35). By contrast, the physiology-guided PRI-
MULTI trial required 50% diameter nonculprit ste-
nosis plus FFR #0.8, or over 90% diameter stenosis
without FFR (36), and the COMPLETE (Complete
vs Culprit-only Revascularization to Treat Multi-
vessel Disease After Primary PCI for STEMI) trial
will include at least a 50% diameter stenosis
plus FFR #0.8, or at least a 70% lesion without
FFR (37).
Preliminary results demonstrated that 56.5% of
nonculprit lesions of at least 50% diameter stenosis
had an FFR >0.8 (38), indicating the same marked
disagreement between anatomy and physiology as
the 38.2% discordance in the acute subset of
the FAME (Fractional Flow Reserve Versus Angiog-
raphy for Multivessel Evaluation) trial (39) or
the 39.1% discordance in the NSTEMI population
of the FAMOUS trial (21). Therefore, 40% to 60%
of angiographically signiﬁcant nonculprit lesions
may have an FFR >0.8 at the time of acute
presentation.
Although anatomic-functional discordance occurs
frequently in both stable and unstable patients, the
clinical effect of both high and low FFR values in
nonculprit lesions in the setting of acute MI remains
to be determined for several reasons. In ACS, mul-
tifocal heterogeneous inﬂammation, endothelial
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vessel disease may associate with subsequent non-
culprit risk not accounted for by FFR. The value of
coronary physiology in the acute setting may also be
open to question, due to changes during the recovery
phase. Just as the myocardium downstream of a
culprit lesion recovers its ﬂow capacity over time
after STEMI (24), the nonculprit myocardium may
undergo a similar process that changes its capacity to
augment ﬂow. However, empirical data suggest that
such changes occur rarely or are only modest and
that nonculprit artery physiology for FFR and IMR
remains valid in the acute setting (40,41).
RANDOMIZED OUTCOMES TRIALS USING PHYSIOLOGY
FOR NONCULPRIT LESIONS. Approximately one-third
of subjects enrolled in the multicenter and interna-
tional FAME trial (328 of 1,005 patients) presented
with unstable angina (UA) or NSTEMI and were
analyzed in a post hoc substudy (39). Note that FAME
excluded patients with STEMI in the preceding
5 days and UA/NSTEMI with high peak creatine
kinase, thus producing a medically stabilized cohort
of modest infarct size. FFR measurement was suc-
cessful in 93% of lesions in the UA/NSTEMI cohort,
which was not signiﬁcantly different than in the sta-
ble population (94%). Although the cohort with acute
coronary disease had a higher event rate than sub-
jects with stable angina (24.1% vs. 18.2% after 2 years;
p ¼ 0.03), there was no difference between them in
the beneﬁt of FFR-guided treatment on outcomes
(relative risk reduction of 19% vs. 18%; p ¼ 0.92).
Outcomes in both groups with acute and stable dis-
ease favored FFR guidance over angiography. How-
ever, due to the smaller size of the UA/NSTEMI
cohort, hard endpoints trended lower with an FFR
strategy, but did not reach statistical signiﬁcance:
death 2.7% versus 4.5%, and MI 8.0% versus 13.5%
(both p > 0.05). Freedom from angina at 2 years did
not differ between an FFR-guided versus an
angiographic-guided strategy in this subgroup with
acute disease (60.7% vs. 64.6%; p ¼ 0.54).
The multicenter FAMOUS-NSTEMI trial in the
United Kingdom focused exclusively on NSTEMI in
350 patients with at least one 30% diameter stenosis
(21). Importantly, a median of 3 days (interquartile
range: 2 to 5 days) elapsed between the index clinical
episode and invasive angiography, reﬂecting the un-
derlying health care system. Subjects were random-
ized equally between FFR- and angiographic-guided
revascularization, although all lesions had successful
FFR measurements in 99.7% of cases, with only 2
coronary dissections attributed to the pressure wire.
After 1 year of clinical follow-up, all-cause death didnot differ signiﬁcantly between the angiographic- and
FFR-guided groups (risk difference 1.1% favoring
angiography; 95% CI: 2.4% to 5.0%; p ¼ 0.54), nor
did spontaneous MI (risk difference 1.1% favoring
angiography; 95% CI: 3.1% to 5.5%; p ¼ 0.69).
Recently, the Danish multicenter PRIMULTI study
enrolled 627 patients with STEMI and a signiﬁcant
(over 50% diameter stenosis) nonculprit lesion in a
major vessel (36). All STEMI culprit lesions were
treated, and nonculprit lesions were randomized to
standard care as per the local routine or to FFR-
guided revascularization (unless over 90% diameter
stenosis visually, in which case no FFR was required)
before hospital discharge, but at least 48 h after the
index procedure. After a minimum follow-up of
1 year, all-cause death did not differ signiﬁcantly
between the 2 groups (HR: 1.4; 95% CI: 0.63 to 3.00;
p ¼ 0.43), but cardiac death trended lower with FFR-
guided revascularization of the nonculprit lesion (HR:
0.56; 95% CI: 0.19 to 1.70; p ¼ 0.29). Nonfatal MI was
statistically unchanged (HR: 0.94; 95% CI: 0.47 to
1.90; p ¼ 0.87). However, future revascularization
was lower in the FFR-guided group after discounting
the initial procedure (HR: 0.31; 95% CI: 0.18 to 0.53;
p < 0.001). No signiﬁcant differences existed among
admissions for signiﬁcant angina (HR: 1.1; 95% CI:
0.75 to 1.70; p ¼ 0.6) or residual angina class.
Two ongoing randomized outcome trials of non-
culprit lesions in STEMI incorporate FFR physiolog-
ical assessment. The multicenter, international
CompareAcute (Comparison Between FFR Guided
Revascularization Versus Conventional Strategy in
Acute STEMI Patients With MVD) trial will enroll 885
subjects with at least a 50% diameter stenosis in a
nonculprit vessel (42); baseline data from the ﬁrst
408 subjects were presented in 2014 (38). Like
PRIMULTI, all culprit lesions will be treated by PCI
with nonculprit lesions randomized to standard care
or FFR-guided revascularization, with a primary
endpoint of all-cause death, MI, any revasculariza-
tion, and cerebrovascular accident. The multicenter,
international COMPLETE trial will enroll 3,900 sub-
jects with either at least a 70% diameter stenosis
without FFR or 50% to 70% diameter stenosis with
FFR #0.8 in a nonculprit vessel (37). Although
the randomized groups are as in PRIMULTI and
CompareAcute, the primary endpoint includes only
cardiovascular-related death and nonfatal MI. Results
from these 2 new trials are anticipated in 2018.
Figure 1 summarizes the existing outcomes trials of
FFR in patients with acute coronary disease.
SUMMARY OF NONCULPRIT PHYSIOLOGICAL
ASSESSMENT TO GUIDE TREATMENT. For the vast
FIGURE 1 FFR in Patients With Acute Coronary Disease
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2777majority of patients who stabilize either before or
rapidly during the index PCI, assessment of FFR
in the acute or semiacute settings has proved to be
safe, and its absolute numeric value is acceptably
reproducible. Importantly, a signiﬁcant discordance
exists between anatomic and physiological assess-
ment of nonculprit severity, with 40% to 60% of
lesions demonstrating an FFR >0.8, just as for stable
CAD (43) (to be reviewed later). Because approxi-
mately 50% of patients with acute coronary disease
undergoing invasive angiography have a noteworthynonculprit stenosis, an objective basis for its inter-
vention or deferral is essential.
Given the reductions in cardiovascular death and
MI seen with routine angiography in patients with
acute coronary disease, trials are needed to deter-
mine if these same endpoints can be improved
by treating the nonculprit lesion. Hypothesis-
generating, yet modestly sized recent trials (<800
patients total) using angiographic criteria alone
have suggested marked beneﬁts of 50% to 70%
reduction in hard events (34,35). By contrast, recent
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2778intermediate-sized, FFR-guided trials of nonculprit
intervention (<1,500 patients total) indicate more
modest or no beneﬁt, as detailed previously. Thus, we
currently lack a consistent or plausible signal of
clinical beneﬁt for routine intervention of nonculprit
lesions in patients with acute coronary disease.
Without a reduction in death or MI, nonculprit PCI
at the acute presentation would at least need to
improve symptoms or future quality of life, including
functional limitation or urgent revascularization.
In conclusion, large, deﬁnitive studies using hard
outcomes are essential to prove any value of physio-
logically guided treatment of nonculprit lesions
in patients with acute coronary disease. Although
COMPLETE meets these criteria, it mixes anatomic
and physiological criteria, thereby providing less
clarity than either strategy alone.
PATIENTS WITH STABLE
CORONARY DISEASE
Stable CAD patients account for approximately 20% to
30% of coronary revascularizations (13,14). However,
the total population of patients with stable coronary
disease (approximately 15.5 million Americans have
known coronary heart disease) dwarfs the number
of patients with acute coronary disease (44). Addi-
tionally, those who present with new chest symptoms
but with no elevation in cardiac biomarkers or
electrocardiographic changes comprise a frequently
encountered category of patients with known or
suspected CAD, which may include patients with or
without known cardiovascular risk factors. Thus,
patients with stable CAD comprise the majority
of clinical practice, but account for a minority of
revascularizations. Notably, revascularization of pa-
tients with stable CAD has failed to improve hard
outcomes, as summarized by the American guidelines
in 2011: “PCI. reduces the incidence of angina. has
not been demonstrated to improve survival in stable
patients . may increase the short-term risk of MI .
does not lower the long-term risk of MI” (45).
Nevertheless, a recent study suggests that this spe-
ciﬁc aspect regarding the potential beneﬁt of revas-
cularization or alternative treatment strategies is
rarely included in informed consent discussions
between cardiologists and their patients (46).
In the future, how will coronary physiology as-
sessments affect the diagnosis and management
of stable CAD patients? For clinical care and trials
alike, an important conceptual step separates
“harder” outcomes of death and MI from “softer”
outcomes of angina relief and recurrent procedures. A
physiological risk-beneﬁt continuum exists that mayprofoundly affect the magnitude, as well as the
method of revascularization (5,47). Coronary physi-
ology already provides objective and quantitative
tools for patient care that may further reﬁne recruit-
ment into outcomes trials of meaningful clinical
endpoints for validation of beneﬁcial treatments.
Prospective randomized trials on the basis of these
concepts are feasible, despite associated practical and
economic challenges (5).
PHYSIOLOGICAL CONTINUUM OF RISK. Outcomes
data over the past several years have identiﬁed a
consistent relationship between coronary physiolog-
ical measurements and subsequent clinical events.
The broadest data have been acquired using either
invasive FFR or noninvasive CFR, although prog-
nostic data is now emerging for several parameters
that combine measurements. Noninvasive CFR equals
the ratio of absolute coronary ﬂow or myocardial
perfusion between hyperemia and rest, and can be
assessed using a variety of technologies, although the
broadest data exists for positron emission tomogra-
phy (PET) (48). Developed as a relative CFR (49),
invasive FFR practically equals the ratio of coronary
to aortic pressure during hyperemia.
In addition to being distinct, yet complimentary
physiological measures of CAD severity, FFR and
noninvasive CFR differentially emphasize revascu-
larization as an outcome. The published prognostic
data on FFR has been more highly inﬂuenced by the
use of revascularization, as opposed to noninvasive
CFR, with generally hard endpoints that have more
ominous prognostic implications. As a ﬁnal distinc-
tion between them, FFR-guided PCI reduces subse-
quent major adverse cardiac events in randomized
trials compared with angiographic-guided PCI and
compared with medical treatment alone. No such
trials exist for CFR. Here, we summarize the existing
studies on the FFR (Figure 2) and CFR (Figure 3)
severity-risk continuum as the basis for discussing
their clinical implications in the next section, which
profoundly reorders assessment of CAD severity from
anatomy to physiology.
A meta-analysis of FFR outcomes studies included
9,173 study-level lesions and 6,961 patient-level
lesions from predominately observational published
data (47). Both types of analysis supported a contin-
uous, inverse relationship between the numeric FFR
value and adverse outcomes, with a parallel increase
in the absolute risk for medically treated lesions
associated with a larger absolute beneﬁt from revas-
cularization. The medical treatment and revasculari-
zation curves generally crossed in the 0.75 to
0.80 range, but the source data was primarily limited
FIGURE 2 Risk Versus Beneﬁt Continuum of FFR
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2779due to confounding by indication. FFR measured
immediately after PCI also showed an inverse rela-
tionship with clinical outcomes, likely reﬂecting
residual diffuse disease.
A retrospective, single-center analysis of 882
deferred lesions explored predictive variables for
subsequent intervention (50). In a multivariable
model, the numeric FFR value remained a signiﬁ-
cant predictor of future revascularization, of which
65% were urgent. For every 0.05 decrease in the
FFR value, the hazard increased by 21% (HR: 1.21;
95% CI: 1.03 to 1.42; p ¼ 0.02) after adjusting for
other factors.
Preliminary data from the randomized, interna-
tional, and multicenter FAME 2 trial focused on the
natural history of 1,027 lesions treated medically in
the FFR #0.8 group and the FFR >0.8 registry (51).
Again, a signiﬁcant and inverse relationship existed
between the FFR value and a clinical composite of
death, MI, and target lesion revascularization. For
every 0.05 decrease in the FFR value, the risk (espe-
cially target lesion revascularization) increased by
31% (HR: 1.308; 95% CI: 1.219 to 1.403; p < 0.001)
after adjusting for other factors.
A multicenter registry in South Korea enrolled de-
ferred coronary lesions of over 30% diameter stenosisby visual estimation with an FFR >0.8 (52). A total of
5,006 patients have been enrolled, for whom pre-
liminary results were presented from 3,534 lesions
that had at least 6 months of clinical follow-up after
deferral from revascularization (53). The 2-year rates
of cardiac death (1.0%) and nonfatal MI (0.9%) high-
light the low-risk natural history of lesions with a
high FFR value. As in other studies, a signiﬁcant, in-
verse relationship existed between the numeric
FFR value and repeated interventions at 2 years.
Another retrospective, single-center analysis of
1,459 patients with FFR lesions between 0.70 and
0.85 compared clinical outcomes after medical ther-
apy versus revascularization (54). Among medically
treated lesions, a signiﬁcant, inverse relationship was
seen between the numeric FFR value and a composite
outcome of death, MI, and revascularization. The
medical therapy and revascularization curves crossed
at an FFR of 0.80, a threshold again biased due to
confounding by indication. All-cause death alone was
higher for medically treated lesions between FFR
0.70 to 0.80 than for FFR 0.81 to 0.85 (HR: 2.62; 95%
CI: 1.28 to 6.8; p < 0.001).
Noninvasive CFR (occasionally termed myocardial
ﬂow or perfusion reserve, although we prefer CFR to
emphasize the fundamental and common physiology)
FIGURE 3 Risk Continuum of Noninvasive CFR
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2780as a binary prognostic variable has been assessed in
several single-center series using cardiac PET or car-
diac magnetic resonance. Binary CFR <2 identiﬁed a
higher risk of cardiac death alone or when combined
with MI, revascularization, and cardiac hospitaliza-
tion in 229 patients over approximately 5 years after
initial medical treatment, even when adjusting for
other variables (55). Similarly, in 677 patients after
initial medical treatment, CFR <2 was an indepen-
dent predictor of both hard events of cardiac death
plus MI alone, and when combined with revascu-
larization and cardiac hospitalization (56). Both
CFR <2.11 and absolute stress ﬂow <1.90 ml/min/g
(derived from the median values in the population)
signiﬁcantly separated risk in 224 patients over about
1 year after initial medical treatment, although only
CFR remained signiﬁcant in a multivariable model(57). A substudy of 222 subjects in MESA demon-
strated an inverse relationship between the predicted
10-year risk of coronary heart disease and absolute
stress ﬂow and CFR (p < 0.0001 for trend) (58).
Global CFR physiologically quantiﬁes the global
burden of diffuse CAD over a spectrum of severity
that directly relates to a continuum of risk. This risk
might be modiﬁable by revascularization (5). Global
CFR <1.5 by PET is associated with a high risk of
coronary events, as compared with global CFR over
2.0 carrying relatively lower risk, and with an inter-
mediate risk in between (59,60). As shown in Figure 4,
coronary artery bypass graft (CABG), but not PCI, in
patients with global CFR <1.6 may modify this high-
risk natural history (61). However, neither PCI nor
CABG had any effect on the natural history of patients
with global CFR $1.6, and the overall cohort was of
FIGURE 4 Potential Beneﬁt of Revascularization for Low CFR
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2781modest size, at 329 patients. These retrospective ob-
servations require randomized outcomes trials
of revascularization or novel medical treatment,
but for now they suggest that the risk/beneﬁt con-
tinuum may be modiﬁed by physiology-guided
revascularization.
Finally, some studies have explored the prognostic
continuum for combined invasive FFR and invasive
CFR measurements. A retrospective, single-center
analysis examined the outcomes of 157 lesions
treated with initial medical therapy (62). Lesions with
both FFR >0.8 and CFR >2 experienced the lowest
rates of approximately 30% combined death, MI, and
revascularization over the subsequent decade of
follow-up. Lesions with FFR #0.8, but CFR >2 had a
slightly higher event rate at 40%, whereas the highest
event rate of 80% occurred in lesions with FFR >0.8,
but CFR #2 (although revascularizations dominated).
On the basis of these and related ﬁndings (63), a
multicenter international pilot study is examining the
hypothesis that PCI in lesions with CFR >2, despite
FFR #0.8, can be safely deferred and treated with
medical therapy alone (64).
IMPLICATIONS OF THE SEVERITY-RISK CONTINUUM
ON HARD OUTCOMES. Disease severity and itsassociated risk represent a continuum that challenges
the patient-speciﬁc selection of diagnostic testing
and management. Precision medicine focuses thera-
pies on those most likely to derive the greatest
beneﬁt. Accordingly, it is helpful to view the design
and interpretation of clinical trials through the con-
tinuum lens. Because fully informed patient consent
includes a “discussion of the pros and cons of the
alternatives” as well as “the uncertainties associated
with the decision” (46), the risk continuum also has
practical implications for clinical care. Moreover, in
the absence of trials proving reduced MI and death,
the common belief by patients and physicians that
PCI will reduce either of these events (65) might be
considered a fundamental violation of true informed
consent. This potential becomes realistic because in a
real-world analysis of discussions with cardiologists,
better-informed patients were less likely to select
invasive angiography and potential PCI (46). For
example, between an FFR of 0.75 and 0.80, the
modestly elevated risk from the stenosis physiology
warrants consideration of other factors, such as the
amount of distal myocardium, severity and pattern of
symptoms, technical feasibility of revascularization,
and ability to tolerate antianginal and dual
FIGURE 5 Severity Stratiﬁcation for Randomized Trials or Informed Interventional
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2782antiplatelet medications. However, the greatly
elevated risk from an FFR <0.60 should tilt the bal-
ance strongly toward revascularization if all other
factors remain equal. We already make these contin-
uous and integrative decisions for blood pressure,
dyslipidemia, and ejection fraction; thus, the appli-
cation to lesion physiology is a natural extension.
No trial comparing optimal medical therapy to
revascularization in patients with stable CAD has
conclusively demonstrated a statistically signiﬁcant
reduction in hard outcomes of death or MI. Until
revascularization trials prove a reduction in hard
events by selecting more severe focal and diffuse CAD
than previously, the risk/beneﬁt continuum remains
the only valid basis for personalized decision-making
with informed consent. This view will likely play such
an important future role in both clinical practice
and trial design that a further discussion of current
trials in stable CAD is essential for revealing this
commonly-overlooked interpretation of what their
data actually shows.The FAME 2 trial showed a nonsigniﬁcant
reduction in death and MI from 8.2% after 2 years
with initial medical therapy to 6.5% with upfront
PCI (HR: 0.79; 95% CI: 0.49 to 1.29; p ¼ 0.35) for
lesions with FFR #0.8 (66). Using these event rates
plus standard assumptions for a power calculation
(2-sided, <0.05 signiﬁcance, 80% power) yields a
trial size of 3,784 patients (5)—over 4-fold higher
than the 888 patients randomized in FAME 2, and
larger than any contemporary revascularization trial
in patients with stable coronary disease: 408 in
MASS II (Medicine, Angioplasty, or Surgery Study)
(67), 1,605 in BARI 2D (Bypass Angioplasty Revas-
cularization Investigation 2 Diabetes) (68), and 2,287
in COURAGE (69). Given the current recruitment
trajectory of ISCHEMIA (now at n ¼ 2,851 [10] of a
target 8,000 after 3 years of enrollment), random-
izing 3,784 patients with stable coronary disease
with FFR #0.8 does not seem feasible within cur-
rent research frameworks.
However, the continuum of risk implies a larger
treatment beneﬁt for more severe lesions. Assume that
lowering the inclusion criterion from FFR#0.8 to#0.7
would increase both the relative beneﬁt (from 0.79 to
0.7 with upfront PCI) and the absolute event rate (from
8.2% to 9%withmedical therapy). Now the sample size
falls from 3,784 to 1,670—a decrease of about 55%—
resulting in a trial comparable in size to BARI 2D and
smaller than COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation).
Not only has sample size decreased, but so too the
absolute number of death and MI events: 277 in the
larger trial to 116 in the smaller trial (5). Thus, exam-
ining for a potential beneﬁt of PCI on hard outcomes in
more severe patients makes a clinical trial both
feasible and more ethical. Figure 5 provides a general
framework for this trial.
Additionally, the typical FFR values around 0.83
seen in a recent diagnostic accuracy study from in-
vestigators seeking to avoid hyperemia (70) (such that
approximately 2 of 3 patients had an FFR >0.8, and
probably 8 of 10 patients had an FFR >0.75) fall
on the ﬂat portion of the risk/beneﬁt continuum,
thereby reducing event rates and hence hampering
the ability to exclude a clinically meaningful inferi-
ority when using resting metrics. In this range of
mild physiology, a more vigorous upstream trial of
medical therapy, coupled with a higher symptom or
noninvasive testing threshold, could likely avoid
invasive angiography completely, without compro-
mising outcomes.
Finally, the risk continuum has implications for
noninvasive physiological testing. Advanced imaging
tools all have similar and high diagnostic
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2783performance versus FFR #0.8: PET (sensitivity 89%,
speciﬁcity 84% [71]), cardiac magnetic resonance
(sensitivity 90%, speciﬁcity 87% [72]), and phy-
siological simulation of FFR on the basis of CT
angiography (sensitivity 89%, speciﬁcity 71% [73]).
However, FFR as a reference standard of severity can
reasonably be challenged due to substantial discor-
dance from adequate or normal quantitative coronary
ﬂow capacity (63) or in patients with insigniﬁcant or
no coronary stenosis (43), historically at low risk.
Although a complete description of stenosis physi-
ology requires both pressure and ﬂow measurements
(48), the risk continuum at very low FFR or CFR
identiﬁes lesions with a worse natural history
potentially beneﬁted by revascularization. At these
lower FFR and CFR values, lesion severity is rarely
underestimated by advanced imaging, with pressure
ﬂow concordance for optimally guiding revasculari-
zation to reduce hard endpoints.
MATCHING REVASCULARIZATION STRATEGY TO
PHYSIOLOGY PROFILE. At its most general, 3 options
exist for treating stable CAD: medical therapy, PCI,
and CABG. Medical therapy forms the foundation of
treatment, although patients differ in their ability
to tolerate and adhere to optimal management. PCI
relieves a focal stenosis, providing improved angina
relief compared with medical therapy (74), but at a
cost of small (but nonzero) procedural risk (18) and
the need for dual antiplatelet therapy of potentially
longer duration (75). CABG may excel at treating
diffuse and complex CAD (76), but with a higher
procedural risk (18) and without the need for dual
antiplatelet therapy.
Historically, the beneﬁt of PCI rested on assump-
tions that are now challenged by the following 2 re-
alizations. First, visual estimation of stenosis severity
performs poorly compared with coronary physiology
(43). Second, unrecognized and unquantiﬁed diffuse
disease carries a similar risk to focal disease (61,77).
This was also illustrated in the PROSPECT study,
wherein nonculprit lesions accounted for a compa-
rable frequency of events versus culprit lesions after
an ACS (11.6% vs. 12.9% over 3 years, respectively)
(11), and in a pooled analysis of post-PCI measure-
ments of FFR that found an inverse relationship
with outcomes due to residual diffuse disease (48).
Although a series of randomized trials has already
moved the evaluation of stenosis severity from
angiography to physiology, speciﬁcally by using FFR
(66,78,79), the awareness regarding diffuse and
microvascular disease is only now emerging.
Matching the strengths of each treatment to
the individual patient implies PCI for focal diseaseof sufﬁcient physiological severity as detailed previ-
ously, but without extreme anatomic complexity (76)
or severe diffuse disease, which may be better treated
by CABG or medical therapy, depending on anatomic
and patient speciﬁcs (5). Distinguishing focal from
diffuse disease thus takes on heightened importance,
and 2 general physiological techniques exist. Inva-
sively, a pressure pullback along the length of the
epicardial artery can separate focal drops in pressure
from diffuse, gradual pressure loss (80). However, a
distal FFR measurement will overestimate the rela-
tive ﬂow increase from treating a focal stenosis in
the presence of diffuse disease, thereby uncoupling
FFR from relative CFR. Noninvasively, a global CFR
or absolute stress ﬂow reduction in the absence of
a relative regional perfusion defect identiﬁes diffuse
disease and/or microvascular dysfunction (63). The
particular strength of CFR using absolute perfusion
measurements resides in its common units for
both focal stenosis and diffuse disease, thereby
quantifying their relative importance or weight for
optimizing the revascularization method (5).
Identifying the physiological pattern affects both
patient care and the design of clinical trials to guide
informed consent. Treating a focal and severe angio-
graphic stenosis that is physiologically mild exposes
patients to procedural risk and heightened antith-
rombotic therapy without improving symptoms or
reducing the risk of hard events (78,79). Treating amild
focal stenosis in a vessel with low FFR due mainly to
diffuse disease leaves the patient at increased residual
risk (47). It is possible that both of these physiology-to-
treatment mismatches took place in prior outcome
trials that failed to ﬁnd beneﬁt of revascularization
compared with medical therapy (69).
CORONARY PHYSIOLOGY TO DIAGNOSE SYMPTOMS
AND GUIDE TREATMENT. Apart from the questions of
altering hard endpoints of death and MI in stable
CAD, we frequently encounter patients with symp-
toms who want to feel better. Of patients without
known CAD who present with new chest pain symp-
toms, only a small minority has a coronary etiology.
For example, in the ROMICAT-II (Rule Out Myocardial
Infarction/Ischemia Using Computer Assisted Tomo-
graphy) trial of 1,000 patients presenting to the
emergency department with symptoms suggestive of
an ACS, but with an initial negative troponin and no
signiﬁcant changes on electrocardiography, 8% of
patients were diagnosed with an ACS (81). Further-
more, 89% of patients with symptoms prompting
emergency medical evaluation in this study had
noncardiac or noncoronary chest pain. The similarly
low rates of revascularization after 90 days seen in
Johnson et al. J A C C V O L . 6 7 , N O . 2 3 , 2 0 1 6
Future of FFR and CFR J U N E 1 4 , 2 0 1 6 : 2 7 7 2 – 8 8
2784the PROMISE (Prospective Multicenter Imaging Study
for Evaluation of Chest Pain) trial of 10,003 out-
patients referred for noninvasive testing (3.2%
with functional testing vs. 6.2% with anatomic
testing; p < 0.001) (82) parallel the ﬁndings in the
emergency department, and both studies excluded
patients with known CAD (81,82).
Thus, on the basis of the selected populations
described in the preceding text, patients with stable
coronary disease without known CAD have a pre-test
probability of approximately 5% for a coronary etiol-
ogy of their chest symptoms. This ﬁgure mirrors the
prevalence of angina pectoris at just over 3% of
the entire adult population in the United States,
resulting in 22,000 hospital discharges each year (44).
Although these ﬁgures imply a small population with
symptomatic, stable epicardial coronary disease, such
patients comprise a signiﬁcant portion of cardiology
practice and resource utilization due to diagnostic
testing, clinic visits, hospital admissions, medication
prescriptions plus associated adverse reactions,
and revascularization procedures plus associated
complications. Coronary physiology may play 2
important roles in symptomatic, patients with stable
coronary disease. First, it may help to separate the
small minority of patients with a coronary etiology for
presenting chest pain from the background majority
with noncoronary or noncardiac diagnoses. Unlike
index CT screening (81,82), upfront physiological
testing can likely screen without increasing unnec-
essary downstream procedures. Second, it may
help to select patients likely to experience superior
angina relief with revascularization compared with
medical therapy, as reported in the FAME 2 (66) and
COURAGE (69) trials.
A wide body of evidence supports invasive quan-
tiﬁcation of coronary physiology to identify symp-
tomatic ﬁxed stenosis and guide improvement using
revascularization. By comparing FFR against a mul-
titest reference standard of exercise electrocardiog-
raphy, exercise single-photon emission computed
tomography perfusion, and dobutamine echocardi-
ography, both before and after revascularization,
the threshold of 0.75 was established almost 20 years
ago in symptomatic patients with “uncertainty about
whether the chest pain was related to reversible
ischemia caused by the moderate stenosis” (49). For
FFR >0.75 lesions in the DEFER trial, upfront PCI
compared with medical therapy did not improve
angina burden or need for antianginal medications
during the subsequent 5 years (78). From 1 month to
5 years, upfront PCI for these stenoses did not in-
crease the proportion of patients with Canadian
Cardiovascular Society (CCS) class I angina (57% vs.67% actually favoring medical therapy; p > 0.05).
Conversely, the FAME 2 trial demonstrated superior
angina relief when treating FFR #0.8 lesions with
PCI compared with medical therapy (66). From 1 to
24 months, upfront PCI for these stenoses reduced
CCS class II to IV angina by about 50% to 60%
compared with initial medical therapy (risk ratios:
0.36, 0.41, 0.39, and 0.49 at 1, 6, 12, and 24 months,
respectively; p # 0.002 at all time points), despite
an approximate 40% crossover to revascularization in
patients treated medically.
However, the improvement in angina after revas-
cularization noted in FAME 2 and other studies may
overestimate beneﬁt due to unblinding of patients and
their physicians (83). Thus, ORBITA (Comparison of
Coronary Angioplasty and Optimum Medical Therapy
Versus Optimal Medical Therapy in the Stable Angina),
an ongoing multicenter study in the United Kingdom,
will randomize a total of 200 patients with stable
angina to real versus sham PCI under blinded condi-
tions (84). Baseline coronary physiology measure-
ments will occur before PCI in all patients, with a
primary endpoint of treadmill exercise time after 6
weeks. The coronary physiology data will provide
valuable predictors for identifying patients whose
angina improves with real PCI, providing an evidence-
based evaluation of the added value for hyperemia
because stable angina occurs with stress, not at rest.
Noninvasive physiological measurements during
angina provide quantitative limits that could form the
basis for future randomized outcomes trials. A study of
1,674 cardiac PET scans imaged absolute stress ﬂow
and CFR with vasodilation using, as the independent
standard, a new or worse perfusion defect during
vasodilation in conjunction with signiﬁcant ST-
segment depression and/or severe angina requiring
pharmacological treatment (85). Absolute stress ﬂows
of 0.91 ml/min/g and CFR of 1.74 demonstrated
excellent diagnostic performance (area under ROC
curves of 0.98 and 0.91, respectively) for identifying
this well-deﬁned ischemia. A multicenter and inter-
national study of 330 patients who underwent both
cardiac PET and invasive angiography with frequent
FFR used an over 90% diameter stenosis or FFR #0.8
as its reference standard (71). Although we should bear
in mind that a complete description of stenosis phys-
iology requires both pressure and ﬂow measurements
(48), absolute stress ﬂow of 2.3 ml/min/g and CFR of
2.5 showed good diagnostic performance (per-vessel
accuracy 85% and 81%, respectively), and these ﬂow
levels have been associated with low risk (59–61).
Noninvasive simulations and resting physiological
predictions of hyperemic conditions assume a uni-
form, predictable, biological response to stress in
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biological variability fundamentally contravenes such
assumptions (86), which can be generally classiﬁed as
due to heterogeneous responses to hyperemia (the
capacity to increase ﬂow varies greatly and unpre-
dictably among patients) or imperfect resolution
(in the case of physiological simulation of FFR from
invasive or noninvasive imaging of anatomy). As a net
effect, these nonstress tools have demonstrated an
imperfect pooled 79% per-vessel accuracy from the
3 major FFRCT diagnostic accuracy studies (87–89), by
the approximate 80% per-lesion accuracy of invasive
resting physiology (70,90,91) to predict invasive
FFR #0.8, and by the Bland-Altman SD for both
techniques of 0.10 to 0.15 compared with invasive
FFR (86,90). For example, a predicted FFR of 0.85
(via invasive resting gradient or noninvasive simula-
tion) could overlap with actual FFR values from 0.70
to 1.0, whose prognosis and treatment differ widely.
Therefore, such resting tools rely on assumptions
that may not be valid when compared with actual
physiological measurements necessary for accurate
personalized therapy.
DIAGNOSIS AND TREATMENT OF ANGINA WITHOUT
OBSTRUCTIVE EPICARDIAL CAD. Two scenarios
occasionally arise that are distinct from classic stable
angina due to a physiologically severe stenosis, as
previously discussed. First, atypical angina can occur
at rest or inconsistently with activity. Chest symp-
toms that occur at rest in patients with stable coro-
nary disease are unlikely to arise solely from a ﬁxed
coronary stenosis. Typically, such complaints are
either noncoronary or result from a variable combi-
nation of ﬁxed stenosis plus functional disease (e.g.,
abnormal blood pressure or heart rate, adrenergic
medications, endothelial dysfunction, or coronary
spasm). As an advantage, vasodilator imaging and
invasive measurements minimize physiological
variability to reveal the severity of ﬁxed disease
alone, whereas exercise stress or dobutamine infu-
sion stimulate physiology severity over and beyond
the ﬁxed structural component (92). Because the
vast majority of functional coronary disease (e.g.,
vasospasm, myocardial bridging, or endothelial
dysfunction) can be treated with widely available,
generally well-tolerated, and relatively inexpensive
medications (e.g., beta-blockers, calcium-blockers,
and nitrates), it has received less attention than
revascularization of ﬁxed coronary disease. Howev-
er, it is increasingly recognized that such conven-
tional therapies do not lead to similar symptom
control as that seen in patients with focal epicardial
stenosis.Beyond symptoms, the presence of angina with
angiographically nonobstructive or normal coronary
arteries may not necessarily associate with low clin-
ical risk. Indeed, a large European registry demon-
strated that patients with angina and normal
coronary arteries or nonobstructive CAD were asso-
ciated with a 52% and 85% increased risk of com-
bined cardiovascular mortality, hospitalization for
MI, heart failure, or stroke, and with 29% and 52%
increased risk of all-cause mortality, respectively,
with no differences between men and women (93).
Similar physiological observations were seen in
studies using invasive (94) or noninvasive (95) CFR
assessment.
Second, classic angina may present without a sig-
niﬁcant stenosis. Interestingly, the group of patients
with angina but FFR >0.75 to 0.80 has a clear subset
with refractory symptoms, despite medical therapy.
In both the DEFER and FAME 2 trials, lesions with
high FFR had inferior angina relief compared with
low FFR lesions that underwent PCI. Speciﬁcally, the
FFR <0.75 cohort treated by initial PCI in the DEFER
trial reached a 72% freedom from angina, whereas
both FFR $0.75 cohorts had lower levels, at 67% and
57% free of angina (p ¼ 0.028) (78). Similarly, the FFR
>0.8 registry of the FAME 2 trial had a similar angina
burden at baseline that improved by 1 month, but
thereafter remained worse than the FFR #0.8 cohort
treated by PCI (risk ratios: 0.47, 0.38, and 0.40 at
6, 12, and 24 months, respectively, favoring low
FFR with PCI; all p # 0.002) despite 12% crossover
to PCI (66).
These subgroup analyses highlight other mecha-
nisms for angina that are separate from a severe
epicardial stenosis. Such functional coronary disease
may be elucidated through a variety of physiolog-
ical techniques, such as noninvasive quantiﬁcation
of global CFR (61), Doppler-derived (62) or bolus
thermodilution-based (20) measures of myocardial
resistance, pressure or ﬂow interrogation of myocar-
dial bridges (96), or provocation testing for endothe-
lial dysfunction (97).
However, currently, only hypothesis-generating
studies suggest potential links to existing thera-
pies. Additionally, many of these therapies cost little
and could thus be tried anyway in patients with
residual symptoms, after excluding signiﬁcant ﬁxed
epicardial disease. Novel systemic therapies for
cardiovascular disease, such as methotrexate and
PCSK9 inhibitors, are currently being tested in gen-
eral populations, and coronary physiology may
provide a risk stratiﬁcation tool to reﬁne their
cost-effective use.
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We conclude by summarizing a vision for the future
of coronary physiology. Given the prominent role of
ACS and invasive procedures in cardiology, our
schema focuses on those themes. Nonetheless, many
(if not most) patients now undergoing interventional
cardiovascular procedures may not meet the severity
criteria for intervention to reduce death and MI
beyond what modern medical treatment can achieve.
It is our view that new interventional trials driven by
quantitatively severe focal and diffuse disease may
help to deﬁne the roles of integrated diagnostic
testing and intervention for reducing hard outcomes.
Of course, no clinical diagnostic test stands apart
from an associated therapy. The future of invasive
FFR, noninvasive CFR, and other related physiolog-
ical measurements rests ﬁrmly on establishing
meaningful links to effective treatments and im-
proved clinical outcomes. For patients with acute
coronary disease, coronary physiology may poten-
tially reﬁne treatment of the culprit lesion. Here,
endpoints of death and MI will dominate clinicaltrials, just as they have in the past for ACS. For both
patients with stable and acute coronary disease with
nonculprit disease, reducing death and MI with
revascularization potentially occurs at the severe end
of the focal physiological spectrum, an area under-
represented in existing trials. We can use the con-
tinuum of risk clariﬁed by coronary physiology to
tailor our discussions with patients to achieve truly
informed consent regarding risks and beneﬁts from
therapy. For the large number of patients with chest
symptoms, physiology measurements identify the
small proportion of them who have coronary disease
with focal severity likely to beneﬁt from revasculari-
zation in addition to medical therapy. Nonepicardial
disease and diffuse CAD remain underexplored as-
pects of coronary physiology for testing of novel
treatments.
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